Bismuth-Based Quad Tx Doesn't Top Levofloxacin Triple Tx

This article originally appeared here.
Share this content:
Bismuth-Based Quad Tx Doesn't Top Levofloxacin Triple Tx
Bismuth-Based Quad Tx Doesn't Top Levofloxacin Triple Tx

FRIDAY, July 14, 2017 (HealthDay News) -- For patients with Helicobacter pylori infection, the addition of bismuth subcitrate to levofloxacin-based triple therapy is not associated with increased effectiveness, although there are no more side effects, according to a study published online June 23 in the Journal of Digestive Diseases.

Tzung-Shiun Wu, from the Kaohsiung Medical University Hospital in Taiwan, and colleagues conducted a prospective study involving 67 patients infected with H. pylori. Patients were randomized to receive levofloxacin plus bismuth-based quadruple therapy (RBAL) for 10 days (33 patients) or levofloxacin-based triple therapy (RAL) for 10 days (34 patients). The response was assessed using endoscopy performed four to eight weeks after eradication.

The researchers found that both groups showed similar eradication rates (84.8 and 67.6 percent for RBAL and RAL, respectively; P = 0.373) in intention-to-treat analysis. There was no significant difference in compliance (P = 1.031); adverse events were also similar between the groups. Most cases of eradication failure were levofloxacin resistant.

"Levofloxacin-resistant rate may be a more important role when choosing second-line therapy," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Medicaid Expansion Ups Preemptive Listing for Kidney Transplant

Medicaid Expansion Ups Preemptive Listing for Kidney Transplant

From pre- to post-expansion period, 59 percent relative increase in Medicaid-covered preemptive listings

BCG Vaccine Tied to Reduced Hyperglycemia in Type 1 Diabetes

BCG Vaccine Tied to Reduced Hyperglycemia in Type ...

Systemic shift in glucose metabolism from oxidative phosphorylation to aerobic glycolysis

Many Physicians Not Prepared for End-of-Life Talks With Patients

Many Physicians Not Prepared for End-of-Life Talks With ...

Additional training, reimbursement may foster these critical conversations, authors say

is free, fast, and customized just for you!




Already a member?

Sign In Now »